Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Crystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103739635A reveals a novel recrystallization method for 1,3,4,6-tetra-O-acetyl-beta-D-mannopyranose, significantly boosting yield and purity for reliable 18F-FDG production.
Patent CN117024496A reveals a one-pot method for Mupiravir intermediates. Achieves 99.9% purity with reduced solvent use and simplified downstream processing for supply chains.
Patent CN101910148B reveals a novel crystallization process for dodecahydro-naphtho-furanyl-carbamate intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Novel resolution process enhances purity and supply continuity for D-Calcium Pantothenate manufacturing reducing costs significantly for global buyers.
Discover the novel salt formation process for Trabectedin intermediate Corey 3. Enhance purity and scalability for pharmaceutical manufacturing with our advanced synthetic routes.
Novel crystalline cephamycin intermediate via salt formation. Enhances stability and purity for cefminox sodium production. Reliable supply chain solution.
Patent CN104341342A reveals ethanol-based DAST synthesis yielding 95% purity. Offers supply chain stability and cost reduction for optoelectronic manufacturing.
Novel resolution method using ethyl acetate and ethanol mixtures ensures high optical purity and yield for scalable antidepressant intermediate production.
Patent CN115894387A reveals a novel oxidation route for prothioconazole metabolites. Achieve 99% purity with scalable, cost-effective synthesis for residue analysis.
Novel linear alkane solvent method improves lidocaine purity to 99.8%. Reduces impurities and enables mother liquor recovery for cost efficiency.
Patent CN102452972A reveals improved oxiracetam preparation with higher purity and yield, offering supply chain stability for pharmaceutical intermediate procurement.
Discover the advanced CN113548993B patent method for Carboprost. Achieve 99%+ purity without chromatography. Ideal for reliable pharmaceutical intermediates supplier partnerships.
Patent CN102985416A details a chromatography-free process for thrombin inhibitor intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN111056939A reveals a novel recrystallization method for (1R,3S)-3-aminocyclopentanol, offering high optical purity and yield for Bictegravir synthesis.
Patent CN111848490A details a novel DMAP-catalyzed route for Nintedanib Ethanesulfonate, offering superior purity and supply chain stability for global pharmaceutical manufacturers.
Patent CN110615811A enables high-purity chiral ligand synthesis via crystallization method eliminating column chromatography thus reducing manufacturing costs and improving supply chain reliability.
Solve bromine impurity challenges in prucalopride synthesis. Our optimized recrystallization method achieves >99.8% purity and 93% yield, reducing supply chain risks for API manufacturers.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.
Eliminate chiral column costs with novel crystallization-based resolution. Achieve >99% ee and 76-78% yield for 6,6'-dihydroxy-5,5'-bisquinoline. Scale to 100MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.